Company: CRL
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001100682-25-000011
Chunk: 166

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-02-19
Form: 10-K
Item: Item 8
Chunk 166
---
 amortized cost which approximates the fair value. The fair value is based on significant other observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2 within the fair value hierarchy.The book value of the Company’s Senior Notes are fixed rate obligations carried at amortized cost. Fair value is based on quoted market prices as well as borrowing rates available to the Company. As the fair value is based on significant other observable outputs, it is deemed to be Level 2 within the fair value hierarchy. The book value and fair value of the Company’s Senior Notes is summarized below:December 28, 2024December 30, 2023Book ValueFair ValueBook ValueFair Value(in thousands)4.25% Senior Notes due 2028$500,000 $473,750 $500,000 $478,100 3.75% Senior Notes due 2029500,000 456,250 500,000 458,100 4.00% Senior Notes due 2031500,000 441,250 500,000 449,350 

10. GOODWILL AND INTANGIBLE ASSETS

GoodwillThe following table provides a rollforward of the changes in the carrying amount of the Company’s goodwill:RMSDSA(1)ManufacturingTotal(in thousands)December 31, 2022$497,710 $1,433,601 $918,592 $2,849,903 Acquisitions— 209,478 — 209,478 Foreign exchange(236)19,355 16,545 35,664 December 30, 2023497,474 1,662,434 935,137 3,095,045 Acquisitions— 17,675 — 17,675 Impairment— — (215,000)(215,000)Foreign exchange(734)(44,458)(5,920)(51,112)December 28, 2024$496,740 $1,635,651 $714,217 $2,846,608 (1) DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010.The decrease in goodwill during fiscal year 2024 is primarily related to the $215.0 million impairment charge recognized in the Manufacturing reportable segment and foreign exchange impacts in the DSA reportable segment; partially